The Wall Street Journal said that the drugmaker plans to test Zilmax in about 250,000 cattle in a randomized, controlled study. But sources say beef producers like Cargill and JBS SA have pushed back against the move. While Merck planned to have the feed additive on the market by this summer, the study has been delayed.
Merck wants to get its cattle feed additive Zilmax back to multimillion-dollar sales. But with lingering reservations from beef producers and sellers, that may be easier said than done--and competition is ramping up in the meantime.
Questcor is disclosing that its immune-system drug Acthar may pose more risks than it had let on. An SEC filing from Thursday reported that 14% of prescriptions written for the drug in 2013 resulted in adverse side effects, up from 9.1% in 2011.
In February and again in May, Merck sent a cease-and-desist order to Alberto Donzelli, head of education, appropriateness, and evidence-based medicine at Milan's public health authority. Donzelli had openly criticized Merck's cholesterol-lowering drug Ezetrol (ezetimibe), which is sold in the U.S. as Zetia. Now the company is doing an about-face.
For the second time in recent months, Pfizer is recalling hundreds of thousands of bottles of a drug when one was found to contain the wrong tablet.
Shares of Regado Biosciences took a nasty beating Thursday evening after the company put out the word that enrollment in its big, self-funded Phase III study of a new anticoagulant had to be put on hold so that a safety monitoring committee could check out "serious adverse events related to allergic reactions."
Bristol-Meyers Squibb recalled six lots of 5 mg single-use vials of Coumadin for Injection due to the presence of particulate matter, but the FDA said the issue does not affect the more prevalent oral formulation of the popular blood thinner.
Biogen's multiple sclerosis drug Tecfidera has racked up $1.38 billion in sales since its launch last April, and now the company can claim another feather in the drug's cap: It has the best safety profile of any of its peers. That's the conclusion of a new report out from AdverseEvents, which analyzes side-effects data filed with the FDA.
Affymax, which 18 months ago appeared poised for big things, is dissolving the company and will pay shareholders pennies for the shares that traded at $27 a share before patient deaths led it to pull its Omontys anemia drug from the market.
In 2004, the FDA warned the public that antidepressant use could increase the risk of suicidal thoughts or actions in adolescents--and it required all makers of antidepressant drugs to add to the drugs a dreaded "black box" warning. Now a group of researchers from Harvard is presenting rather compelling evidence that the FDA's action might have been a mistake.